Similar articles

• The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.

  Kingsberg SA, Simon JA, Goldstein I. Kingsberg SA, et al. J Sex Med. 2008 Sep 2;5 Suppl 4:182-93; quiz 193. doi: 10.1111/j.1743-6109.2008.00961.x. J Sex Med. 2008. PMID: 18783534 Review.
• Androgens, health and sexuality in women and men.

  Wylie K, Rees M, Hackett G, Anderson R, Bouloux PM, Cust M, Goldmeier D, Kell P, Terry T, Trinick T, Wu F. Wylie K, et al. Maturitas. 2010 Nov;67(3):275-89. doi: 10.1016/j.maturitas.2010.07.011. Epub 2010 Sep 18. Maturitas. 2010. PMID: 20851539
• Needs assessment.

  [No authors listed] [No authors listed] J Sex Med. 2008 Sep 2;5 Suppl 4:179. doi: 10.1111/j.1743-6109.2008.00962.x. J Sex Med. 2008. PMID: 18783532 No abstract available.
• Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.

  Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Kingsberg S, et al. J Sex Med. 2007 Jul;4(4 Pt 1):1001-8. doi: 10.1111/j.1743-6109.2007.00526.x. J Sex Med. 2007. PMID: 17627745 Clinical Trial.
• Placebo response in the treatment of women's sexual dysfunctions: a review and commentary.

  Bradford A, Meston CM. Bradford A, et al. J Sex Marital Ther. 2009;35(3):164-81. doi: 10.1080/00926230802716302. J Sex Marital Ther. 2009. PMID: 19360517 Review.